이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

정신분열증의 부정적인 증상과 인지를 개선하기 위한 간헐적인 세타 버스트 자극 (ITBS-NKS-2024)

2026년 9월 15일 업데이트: Schülke, Rasmus Dr., Hannover Medical School

Intermittierende 세타 버스트 자극 Zur Verbesserung Von Negativsymptomatik 및 Kognition Bei Schizophrenie

The planned randomized, sham-controlled, double-blind, monocentric study aims to evaluate the effectiveness of intermittent Theta-Burst Stimulation (iTBS) on negative symptoms and cognitive deficits in schizophrenia. Both the cerebellar vermis and the left dorsolateral prefrontal cortex will be stimulated successively within the same session.

The goal of this trial is to learn if intermittent theta-burst stimulation (iTBS) of the cerebellum and the left dorsolateral prefrontal cortext (DLPFC) can treat negative symptoms and improve cognition in patients with schizophrenia. The main question it aims to answer is:

Does iTBS of the cerebellum and the left DLPFC improve negative symptoms in patients with schizophrenia? Researchers will compare iTBS to sham stimulation to see if iTBS improves negative symptoms.

Participants will:

  • Receive 10 sessions of iTBS over the course of 2 weeks
  • Undergo extensive examination before iTBS treatment, immediately after iTBS treatment and 4 weeks after iTBS treatment. The examination includes assessment of negative symptoms; psychometric assessment of cognition, social cognition, depressive symptoms; functional magnetic resonance imaging; assessment of eye movements; blood and saliva sampling; assessment of adverse events and stimulation associated sensations.

The study thus seeks to determine whether iTBS of the fronto-cerebellar network might improve negative symptoms and cognition by altering the network's functional activity. Additionally, it will investigate whether a pro-inflammatory cytokine profile could affect iTBS outcomes and whether inflammatory markers could be affected by iTBS.

연구 개요

연구 유형

중재적

등록 (추정된)

60

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Lower Saxony
      • Hanover, Lower Saxony, 독일, 30625
        • 모병
        • Hannover Medical School
        • 연락하다:
        • 수석 연구원:
          • Rasmus Schülke, MD (Dr. med.)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Diagnosis of schizophrenia (ICD-10: F20.-)
  • Age: 18-65 years
  • Ability to give informed consent
  • Signed informed consent form

Exclusion Criteria:

  • Any electronic implants
  • Non-MRI-compatible metal implants (e.g., pacemaker, cochlear implant, insulin pump, metal fragment injuries, work in the metal-processing industry)
  • Non-TMS-compatible metal implants (compatible items include: earrings, piercings, dental fillings, crowns, implants)
  • Claustrophobia
  • Epilepsy
  • History of traumatic brain injury within the last 3 months
  • History of stroke
  • Active central nervous system (CNS) infection
  • History of CNS infection within the last 3 months
  • Pregnancy
  • Current drug, medication, or alcohol abuse
  • Simultaneous participation in another clinical trial
  • Planned changes in psychopharmacological medication within the next 2 weeks
  • Severe physical illnesses that could endanger the patient, affect the examinations or make the MRI scanning cause additional burden

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: iTBS

Active intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex

Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex

가짜 비교기: Sham iTBS

Sham intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex

Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in negative symptoms
기간: From enrollment to the end of iTBS treatment

Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points.

From enrollment to the end of iTBS treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Change in negative symptoms at 4-week follow-up
기간: From enrollment to follow-up 4 weeks after the end of iTBS treatment

Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points.

From enrollment to follow-up 4 weeks after the end of iTBS treatment
Speech-gesture rating task
기간: From enrollment to the end of iTBS treatment

Accuracy and speed of evaluations in the Speech-Gesture Rating Task.

From enrollment to the end of iTBS treatment
Speech-gesture rating task at 4-week follow-up
기간: From enrollment to follow-up 4 weeks after the end of iTBS treatment

Accuracy and speed of evaluations in the Speech-Gesture Rating Task at 4-week follow-up.

From enrollment to follow-up 4 weeks after the end of iTBS treatment
Eye-Tracking Task
기간: From enrollment to the end of iTBS treatment

Changes in eye movements in the Eye-Tracking Task.

From enrollment to the end of iTBS treatment
Eye-Tracking Task at 4-week follow-up
기간: From enrollment to 4 weeks after the end of iTBS treatment

Changes in eye movements in the Eye-Tracking Task at 4-week follow-up.

From enrollment to 4 weeks after the end of iTBS treatment
Reading the Mind in the Eyes Test
기간: From enrollment to 4 weeks after the end of iTBS treatment

Reading the Mind in the Eyes Test.

From enrollment to 4 weeks after the end of iTBS treatment
Reading the Mind in the Eyes Test at 4-week follow-up
기간: From enrollment to 4 weeks after the end of iTBS treatment

Reading the Mind in the Eyes Test at 4-week follow-up.

From enrollment to 4 weeks after the end of iTBS treatment
N-Back Test
기간: From enrollment to the end of iTBS treatment

Working memory performance in the N-Back Test (sensitivity index).

From enrollment to the end of iTBS treatment
N-Back Test at 4-week follow-up
기간: From enrollment to the end of iTBS treatment

Working memory performance in the N-Back Test (sensitivity index) 4 weeks after the end of iTBS treatment.

From enrollment to the end of iTBS treatment
FMRI: Resting-state functional connectivity
기간: From enrollment to the end of iTBS treatment

Changes in resting-state functional connectivity in functional magnetic resonance imaging. Focus on connectivity between cerebellar vermis and DLPFC.

From enrollment to the end of iTBS treatment
FMRI: Resting-state functional connectivity at 4-week follow-up
기간: From enrollment to 4 weeks after the end of iTBS treatment

Changes in resting-state functional connectivity in functional magnetic resonance imaging. Focus on connectivity between cerebellar vermis and DLPFC.

From enrollment to 4 weeks after the end of iTBS treatment
FMRI: Task-related functional connectivity
기간: From enrollment to the end of iTBS treatment

Changes in task-related functional connectivity in functional magnetic resonance imaging, for the N-Back-task and the speech-gesture rating task.

From enrollment to the end of iTBS treatment
FMRI: Task-related functional connectivity at 4-week follow-up
기간: From enrollment to 4 weeks after the end of iTBS treatment

Changes in task-related functional connectivity in functional magnetic resonance imaging, for the N-Back-task and the speech-gesture rating task.

From enrollment to 4 weeks after the end of iTBS treatment
Inflammatory cytokines
기간: From enrollment to the end of iTBS treatment

Concentrations of inflammatory cytokines (especially IL-6 and TNF-α) in serum and saliva.

From enrollment to the end of iTBS treatment
Inflammatory cytokines at 4-week follow-up
기간: From enrollment to 4 weeks after the end of iTBS treatment

Concentrations of inflammatory cytokines (especially IL-6 and TNF-α) in serum and saliva.

From enrollment to 4 weeks after the end of iTBS treatment
Stimulation-associated perceptions
기간: From the beginning of each iTBS stimulation to after the end of each iTBS stimulation

Stimulation-associated perceptions, measured using the TMS Adverse Events and Associated Sensations Questionnaire (TMSensQ, Section IV), after each iTBS session.

From the beginning of each iTBS stimulation to after the end of each iTBS stimulation
Therapy dropout rate
기간: From the beginning of iTBS treatment to the end of iTBS treatment

Therapy dropout rate (i.e. study termination).

From the beginning of iTBS treatment to the end of iTBS treatment
Serious Adverse Events (SAEs)
기간: From the beginning of iTBS treatment to the end of iTBS treatment

Serious Adverse Events (SAEs), measured using TMSensQ (Section V).

From the beginning of iTBS treatment to the end of iTBS treatment
Self-reported depression: BDI-II
기간: From enrollment to the end of iTBS-treatment

Self-reported depression, measured using the Beck Depression Inventory-II (BDI-II). Higher scores correspond to more depressive symptoms. The minimum total score is 0 points, the maximum total score is 63 points.

From enrollment to the end of iTBS-treatment
Self-reported depression at 4-week follow-up: BDI-II
기간: From enrollment to 4 weeks after the end of iTBS-treatment

Self-reported depression, measured using the Beck Depression Inventory-II (BDI-II). Higher scores correspond to more depressive symptoms. The minimum total score is 0 points, the maximum total score is 63 points.

From enrollment to 4 weeks after the end of iTBS-treatment
Self-rated gesture perception and production: BAG
기간: From enrollment to the end of iTBS-treatment

Change in self-rated gesture perception and production, measured using the Brief Assessment of Gestures (BAG) questionnaire. Higher BAG scores correspond to greater engagement with or reliance on gestures in communication and indicate stronger tendencies to produce or perceive gestures effectively in different contexts. The minimum total score is 12 points, the maximum total score is 60 points.

From enrollment to the end of iTBS-treatment
Self-rated gesture perception and production at 4-week follow-up: BAG
기간: From enrollment to 4 weeks after the end of iTBS-treatment

Change in self-rated gesture perception and production, measured using the Brief Assessment of Gestures (BAG) questionnaire. Higher BAG scores correspond to greater engagement with or reliance on gestures in communication and indicate stronger tendencies to produce or perceive gestures effectively in different contexts. The minimum total score is 12 points, the maximum total score is 60 points.

From enrollment to 4 weeks after the end of iTBS-treatment
Epigenetic changes of neurotrophic and immunological factors
기간: From enrollment to the end of iTBS treatment

Exploratory molecular biological investigations focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, t-PA, S100A10) factors.

From enrollment to the end of iTBS treatment
Epigenetic changes of neurotrophic and immunological factors at 4-week follow-up
기간: From enrollment to 4 weeks after the end of iTBS treatment

Exploratory molecular biological investigations focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, t-PA, S100A10) factors.

From enrollment to 4 weeks after the end of iTBS treatment
Concentrations of markers of neuronal damage
기간: From enrollment to the end of iTBS treatment

Concentrations of markers of neuronal damage (e.g., NSE, S100-β) in serum.

From enrollment to the end of iTBS treatment
Concentrations of markers of neuronal damage at 4-week follow-up
기간: From enrollment to 4 weeks after the end of iTBS treatment

Concentrations of markers of neuronal damage (e.g., NSE, S100-β) in serum.

From enrollment to 4 weeks after the end of iTBS treatment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Rasmus Schülke, MD (Dr. med.), Hannover Medical School

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 4월 8일

기본 완료 (추정된)

2026년 12월 31일

연구 완료 (추정된)

2026년 12월 31일

연구 등록 날짜

최초 제출

2024년 12월 14일

QC 기준을 충족하는 최초 제출

2024년 12월 14일

처음 게시됨 (실제)

2024년 12월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 15일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

IPD 계획 설명

Whether IPD may be shared has not yet been decided. IPD might not be shared due to data protection laws.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다